Amryt Pharma (Nasdaq:AMYT) - Prezzo delle azioni, notizie e analisi

AMYT Panoramica delle azioni

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases.

Informazioni sull'azienda

AMYT analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	5/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Si prevede che gli utili cresceranno del 53.88% all'anno

Gli utili sono cresciuti del 34.4% all'anno negli ultimi 5 anni

Analisi del rischio

Non sono stati rilevati rischi per AMYT dai nostri controlli di rischio.

Amryt Pharma plc Concorrenti

Evolus

NasdaqGM:EOLS

US$1.1b

ANI Pharmaceuticals

NasdaqGM:ANIP

US$1.1b

Collegium Pharmaceutical

NasdaqGS:COLL

US$1.1b

Liquidia

NasdaqCM:LQDA

US$926.5m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Amryt Pharma
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$14.70
Massimo di 52 settimane	US$14.77
Minimo di 52 settimane	US$6.41
Beta	0.75
1Variazione di 1 mese	0.96%
Variazione a 3 mesi	-0.14%
Variazione di 1 anno	86.55%
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	84.91%

Notizie e aggiornamenti recenti

Recent updates

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

Oct 18

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

Sep 16

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Sep 08

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

Jul 14

Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept

Feb 04

Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder

Dec 23

Amryt Group's Lojuxta receives marketing approval in Brazil

Dec 09

Rendimenti per gli azionisti

	AMYT	US Pharmaceuticals	US Mercato
7D	0.7%	-5.0%	-1.9%
1Y	86.5%	14.1%	30.4%

Ritorno vs Industria: AMYT ha superato il US Pharmaceuticals che ha restituito 14.1 % nell'ultimo anno.

Rendimento vs Mercato: AMYT ha superato il mercato US che ha restituito 30.4 % nell'ultimo anno.

Volatilità dei prezzi

Is AMYT's price volatile compared to industry and market?
AMYT volatility
AMYT Average Weekly Movement	0.4%
Pharmaceuticals Industry Average Movement	9.4%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Prezzo delle azioni stabile: Il prezzo delle azioni di AMYT è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di AMYT è diminuita da 16% a 0% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2015	289	Joe Wiley	www.amrytpharma.com

Amryt Pharma plc Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Amryt Pharma con la sua capitalizzazione di mercato?
AMYT statistiche fondamentali
Capitalizzazione di mercato	US$940.67m
Guadagni(TTM)	-US$790.00k
Ricavi(TTM)	US$243.62m

3.9x

Rapporto P/S

-1,191x

Rapporto P/E

AMYT è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
AMYT Conto economico (TTM)
Ricavi	US$243.62m
Costo del fatturato	US$111.31m
Profitto lordo	US$132.32m
Altre spese	US$133.11m
Guadagni	-US$790.00k

Ultimi guadagni dichiarati

Sep 30, 2022

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.012
Margine lordo	54.31%
Margine di profitto netto	-0.32%
Rapporto debito/patrimonio netto	64.3%

Come si è comportato AMYT nel lungo periodo?

Vedi performance storica e confronto

AMYT Panoramica delle azioni

Premi

Analisi del rischio

Amryt Pharma plc Concorrenti

NasdaqGM:EOLS

US$1.1b

NasdaqGM:ANIP

US$1.1b

NasdaqGS:COLL

US$1.1b

NasdaqCM:LQDA

US$926.5m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH

Amryt Announces European Commission Approves Mycapssa® for the Treatment of Acromegaly

Amryt Pharma plc Re-Affirms Revenue Guidance for the Year 2022

Amryt Pharma plc to Report Q3, 2022 Results on Nov 03, 2022

Amryt Announces COMP Adopts Positive Opinion on Orphan Disease Designation for Mycapssa for Treatment of Acromegaly

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta (Metreleptin)

Recent updates

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH

Amryt Announces European Commission Approves Mycapssa® for the Treatment of Acromegaly

Amryt Pharma plc Re-Affirms Revenue Guidance for the Year 2022

Amryt Pharma plc to Report Q3, 2022 Results on Nov 03, 2022

Amryt Announces COMP Adopts Positive Opinion on Orphan Disease Designation for Mycapssa for Treatment of Acromegaly

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta (Metreleptin)

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez(R) in Great Britain

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez(R) in Great Britain

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Amryt Pharma plc Provides Earnings Guidance for the Full Year 2022

Amryt Pharma plc to Report Q2, 2022 Results on Aug 04, 2022

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa(R) (oral octreotide) for the Treatment of Carcinoid Syndrome

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA

Amryt Announces European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB

Amryt's Filsuvez gets approval in EU to treat rare skin disorder

Amryt Presents Data for Mycapssa (Oral Octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa(R) (oral octreotide) at ENDO 2022

Amryt Pharma plc, Annual General Meeting, Jun 30, 2022

Amryt Pharma plc Announces New Patent for Mycapssa®

Amryt Pharma plc Reaffirms Revenue Guidance for Fiscal Year 2022

CHMP Adopts positive opinion for Filsuvez(R) for the treatment of Dystrophic and Junctional EB

Amryt Pharma plc to Report Q1, 2022 Results on May 04, 2022

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients

Amryt Announces Successful Bioavailability Study for Mycapssa® (Octreotide Capsules)

Amryt Receives Complete Response Letter from the U.S. Food and Drug Administration for Oleogel-S10 NDA

Amryt Announces Oleogel-S10 EMA Regulatory Update

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide)

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients

Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions

Amryt Pharma plc Provides Update on Regulatory Review Process for Oleogel-S1

Amryt Announces the Cancellation of Admission of Its Ordinary Shares to Trading on AIM

Amryt Pharma plc Revises Revenue Guidance for the Year 2021

Amryt Pharma plc Announces Earnings Guidance for the Fiscal Year 2021

Amryt Pharma plc completed the acquisition of Chiasma, Inc. from MPM Capital and others.

U.S. Food and Drug Administration Confirms Amryt’s New Drug Application for Oleogel-S10 Will Not Require an Advisory Committee Meeting

U.S. Food and Drug Administration Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

Amryt Pharma plc entered into an agreement to acquire Chiasma, Inc. from MPM Capital and others for approximately $290 million.

Chiasma surges on merger agreement with Amryt

Amryt and Medison Pharma Canada Sign Distribution Agreement for Myalepta (Metreleptin) in Canada

Amryt Pharma plc to Report Q4, 2020 Results on Mar 04, 2021

Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel

Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept

Amryt Pharma plc Receives Reimbursement Approval from Nice for Myalepta in England and Wales

Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder

Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (Lomitapide) in Saudi Arabia

Amryt Group Receives Marketing Authorisation Approval for Lojuxta in Brazil

Amryt Group's Lojuxta receives marketing approval in Brazil

Amryt Pharma plc Raises Sales Guidance for the Full Year 2020

Amryt Announces Positive Results from Phase 3 Trial of Filsuvez® in Epidermolysis Bullosa

Amryt Signs Distribution Agreement with Swixx BioPharma AG

Amryt and Swixx Sign Distribution Deal for Lojuxta

Amryt Pharma plc to Report Q3, 2020 Results on Nov 05, 2020

Amryt Pharma Intends to Cancel the Admission of the Ordinary Shares to Trading on the Euronext Growth Market

Rendimenti per gli azionisti

Volatilità dei prezzi